Key Takeaways
- The US FDA approved updated mRNA COVID-19 vaccines to better protect against currently circulating variants, including the Omicron KP.2 strain.
- The updated vaccines are designed to provide better protection against currently circulating variants, including the Omicron KP.2 strain.
- The updated vaccines are approved for individuals 12 years of age and older for Comirnaty and Spikevax, and for individuals 6 months through 11 years of age for Moderna and Pfizer-BioNTech COVID-19 Vaccines.
Los Angeles: The US Food and Drug Administration (FDA) approved and granted emergency use authorisation for updated mRNA COVID-19 vaccines to better protect against currently circulating variants.
The FDA said on Thursday that the updated vaccines will target the Omicron variant KP.2 strain.
“Given waning immunity of the population from previous exposure to the virus and from prior vaccination, we strongly encourage those who are eligible to consider receiving an updated COVID-19 vaccine to provide better protection against currently circulating variants,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
“The updated mRNA COVID-19 vaccines include Comirnaty and Spikevax, both of which are approved for individuals 12 years of age and older, and the Moderna COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, both of which are authorised for emergency use for individuals 6 months through 11 years of age,” the FDA said in a press release.
